Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.
A Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease .
10 United States sites
4 Tunisia sites
3 Lebanon sites
1 Greece site
1 Italy site
1 Netherlands site
1 Oman site
18 to 65 Years
HbSS
Phase 2
This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of FT-4202 and test how well FT-4202 works compared to placebo to improve the amount of hemoglobin in the blood and to reduce the number of vaso-occlusive crises (times when the blood vessels become blocked and cause pain).
9 United States sites
12 to 65 Years
Phase 2/Phase 3
The Dissemination and Implementation of Stroke Prevention Looking at the Care Environment (DISPLACE) study is a multi-center, national, National Heart, Lung and Blood Institute (NHLBI)-funded grant to look at the real-world implementation of stroke prevention guidelines (STOP Protocol) in which transcranial Doppler (TCD), a measure of cerebral blood vessel velocity, is used to screen for stroke risk in children ages 2-16 with sickle cell anemia (SCA).
15 United States sites
2 to 7 Years
N/A
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of SHP655 in participants with baseline health sickle cell disease (SCD) and SCD with acute vaso-occlusive crisis (VOC).
14 United States sites
18 to 65 Years
HbSS
Phase 1/Phase 2
FT-4202 is an oral small-molecule agonist of pyruvate kinase red blood cell isozyme (PKR) being developed for the treatment of hemolytic anemias.
19 United States sites
12 to 65 Years
Phase 1
Open Label Extension Study of Voxelotor Clinical Trial Participants with Sickle Cell Disease Who Participated in Voxelotor Clinical Trials .
24 United States sites
6 United Kingdom sites
4 Egypt sites
3 Kenya sites
3 Turkey sites
2 Lebanon sites
2 Netherlands sites
1 Canada site
1 France site
1 Oman site
1 Italy site
> 12 Years
Phase 3
